Resistance to Plazomicin: An Analysis of the Evidence from In Vitro Antimicrobial Susceptibility Studies
Antibiotics · 30.05.2026 · 15 (6) · 559
DOI: 10.3390/antibiotics15060559 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 30.05.2026. Verfasst von George Fanariotis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 15123 Athens, Greece. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Plazomicin, a novel, semi-synthetic aminoglycoside designed to overcome most aminoglycoside-modifying enzymes (AMEs), represents a therapeutic alternative to traditional aminoglycosides for complicated urinary-tract infections (cUTIs). In this review, we sought to evaluate the available data on drug resistance.
Methods
We performed a thorough search across four databases (PubMed, Embase, Scopus, and Web of Science) from their inception to 4 November 2025 to identify relevant studies. The published Clinical and Laboratory Standards Institute (CLSI) antimicrobial susceptibility breakpoints for Enterobacterales were applied.
Results
Fifty-five studies, out of a total of 905 records originally identified, were eligible for data extraction and analysis, yielding antimicrobial susceptibility data for 80,159 clinical isolates. The overall resistance of consecutive Enterobacterales isolates to plazomicin was 0–9.4%, and specifically for Escherichia coli and Klebsiella spp. isolates were up to 4.7% and 15.2%, respectively. Among selected isolates with specific resistance mechanisms, the resistance of carbapenem-resistant Enterobacterales (CRE) was 1.8–67.6%, and specifically for carbapenem-resistant E. coli and Klebsiella spp. isolates, 0–10% and 0.3–90%, respectively. Among multi-drug-resistant (MDR) isolates, up to 24.6% of MDR Klebsiella spp. isolates and up to 15% of MDR E. coli isolates were resistant to plazomicin. Among non-fermenting Gram-negative bacteria, the MIC90 values were consistently high.
Conclusions
The demonstrated high activity of plazomicin against consecutive Enterobacterales isolates and the considerable, yet variable, activity against selected resistant isolates suggest its consideration as a valuable option in the treatment of complicated urinary-tract infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 15123 Athens, Greece.
- School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.
- Department of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA.
ORCID-Profile: George Fanariotis, Iva D Tzvetanova
Zitieren
APA
Fanariotis, G., Poziou, P., Romanos, L. T., Tzvetanova, I. D., & Falagas, M. E. (2026). Resistance to Plazomicin: An Analysis of the Evidence from In Vitro Antimicrobial Susceptibility Studies. Antibiotics, 15(6), 559. https://doi.org/10.3390/antibiotics15060559
Vancouver
Fanariotis G, Poziou P, Romanos LT, Tzvetanova ID, Falagas ME. Resistance to Plazomicin: An Analysis of the Evidence from In Vitro Antimicrobial Susceptibility Studies. Antibiotics. 2026;15(6):559. doi:10.3390/antibiotics15060559
BibTeX
@article{Fanariotis2026,
author = {Fanariotis, George and Poziou, Panagiota and Romanos, Laura T and Tzvetanova, Iva D and Falagas, Matthew E},
title = {Resistance to Plazomicin: An Analysis of the Evidence from In Vitro Antimicrobial Susceptibility Studies},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {6},
pages = {559},
doi = {10.3390/antibiotics15060559}
}
EUVIMED